CRISPR Therapeutics (CRSP) Is Considered a Good Investment by Brokers: Is That True?Zacks Investment Research • 01/12/26
CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2026 MilestonesGlobeNewsWire • 01/12/26
CRISPR Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/05/26
These 2 Healthcare Stocks Beat the Market in 2025. Should You Buy Them in 2026?The Motley Fool • 12/26/25
CRISPR Therapeutics AG (CRSP) Stock Falls Amid Market Uptick: What Investors Need to KnowZacks Investment Research • 12/23/25
CRISPR Therapeutics CRISPR Therapy Shows 90% Response Rate In Aggressive Blood CancerBenzinga • 12/22/25
CRISPR Therapeutics Provides Broad Update on Zugocaptagene Geleucel (Zugo-cel; formerly CTX112™) in Autoimmune Diseases and Hematologic MalignanciesGlobeNewsWire • 12/22/25
Why Is CRISPR Therapeutics (CRSP) Up 3.3% Since Last Earnings Report?Zacks Investment Research • 12/10/25
Cathie Wood's Buys And Rumors Aside, Here's Why Crispr Therapeutics Is A Strong BuySeeking Alpha • 12/04/25
Meet the Beaten-Down Biotech Stock Cathie Wood Loves That Wall Street Says May Soar 50%The Motley Fool • 11/30/25
CRISPR Therapeutics Post Q3 Earnings: Testing Investor Patience, But Still A BuySeeking Alpha • 11/13/25